Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis.

Tomlinson, Anneka; Efthimiou, Orestis; Boaden, Katharine; New, Emma; Mather, Sarah; Salanti, Georgia; Imai, Hissei; Ogawa, Yusuke; Tajika, Aran; Kishimoto, Sanae; Kikuchi, Sino; Chevance, Astrid; Furukawa, Toshi A; Cipriani, Andrea (2019). Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. Evidence-Based Mental Health, 22(2), pp. 61-66. BMJ Publishing Group 10.1136/ebmental-2019-300087

[img] Text
Tomlinson EbidBasedMentHealth 2019_epub.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (194kB) | Request a copy
[img]
Preview
Text
Tomlinson EvidBasedMentHealth 2019_postprint.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (200kB) | Preview

INTRODUCTION We have recently compared all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. Here we present a protocol for a network meta-analysis aimed at extending these results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults. METHODS AND ANALYSIS We will include all double-blind randomised controlled trials comparing one active drug with another or with placebo in the acute treatment major depression in adults. We will compare the following active agents: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main outcomes will include the total number of patients experiencing specific adverse events; experiencing serious adverse events; and experiencing at least one adverse event. Published and unpublished studies will be retrieved through relevant database searches, trial registries and websites; reference selection and data extraction will be completed by at least two independent reviewers. For each outcome we will undertake a network meta-analysis to synthesise all evidence. We will use local and global methods to evaluate consistency. We will perform all analyses in R. We will assess the quality of evidence contributing to network estimates with the Confidence in Network Meta-Analysis web application. DISCUSSION This work will provide an in- depth analysis and an insight into the specific adverse events of individual antidepressants. ETHICS AND DISSEMINATION This review does not require ethical approval. PROSPERO REGISTRATION NUMBER CRD42019128141.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Efthimiou, Orestis and Salanti, Georgia

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1362-0347

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

24 Apr 2019 08:55

Last Modified:

24 Oct 2019 11:20

Publisher DOI:

10.1136/ebmental-2019-300087

PubMed ID:

30996028

Uncontrolled Keywords:

adult psychiatry

BORIS DOI:

10.7892/boris.130283

URI:

https://boris.unibe.ch/id/eprint/130283

Actions (login required)

Edit item Edit item
Provide Feedback